Eczema Global Market Report 2025

Eczema is a chronic inflammatory skin condition marked by redness, itching, dryness, and irritation. It results from a combination of genetic and environmental factors, leading to a weakened skin barrier and an overactive immune response. While eczema can affect individuals of all ages, it is more common in children. The condition often occurs in flare-ups triggered by allergens, irritants, stress, or climate changes.

The primary types of eczema include atopic dermatitis, contact dermatitis, seborrheic dermatitis, and other variations. Atopic dermatitis, commonly referred to as eczema, is a chronic skin disorder characterized by itchy, red, and inflamed skin, often aggravated by allergens, irritants, or stress. Treatment options for eczema include topical treatments, oral medications, biologics, and phototherapy. The condition affects various age groups, including children, adults, and the elderly, and is managed across different healthcare settings such as hospitals, clinics, dermatology centers, home care, and pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The eczema market research report is one of a series of new reports from The Business Research Company that provides eczema market statistics, including the eczema industry global market size, regional shares, competitors with the eczema market share, detailed eczema market segments, market trends, and opportunities, and any further data you may need to thrive in the eczema industry. This eczema market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The eczema market size has grown strongly in recent years. It will grow from $16.41 billion in 2024 to $17.76 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing prevalence of autoimmune diseases, rising eczema cases, increasing approvals from authorities, rising incidences of air pollutants, and increasing burden of allergic reactions.

The eczema market size is expected to see strong growth in the next few years. It will grow to $24.15 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to increasing demand for treatment atopic dermatitis, increasing operational activities, increasing awareness of eczema, increasing incorporation of biologics, increasing adoption of telemedicine platform. Major trends in the forecast period include strategic collaboration, emerging therapies, injectable drugs, and personalized medicine.

The forecast of 8.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper treatment access by raising costs of JAK inhibitors and biologic creams imported from the UK and Denmark, worsening chronic skin condition management. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of autoimmune disorders is expected to drive the expansion of the eczema market in the coming years. Autoimmune disorders occur when the body's immune system mistakenly attacks healthy cells, tissues, or organs, leading to inflammation and damage. The growing incidence of these conditions is linked to genetic susceptibility, environmental factors, infections, dietary changes, and lifestyle influences such as stress and exposure to pollutants. Autoimmune diseases such as psoriasis, lupus, and rheumatoid arthritis are associated with dysregulated immune responses, increasing the likelihood of eczema and other inflammatory skin conditions. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Consequently, the increasing prevalence of autoimmune disorders is fueling the growth of the eczema market.

Leading companies in the eczema market are focusing on developing innovative products, such as advanced eczema care creams, to improve treatment effectiveness and meet the growing demand for specialized skincare solutions. Eczema care creams are formulated to soothe, hydrate, and protect affected skin, reducing itching, inflammation, and dryness. For instance, in September 2024, Dove, a UK-based personal care brand, launched a new Eczema Care range for babies, including the Baby Dove Eczema Care Soothing Bath Treatment and the Baby Dove Eczema Care Cream. This product line is designed specifically for infants with eczema, featuring 100% skin-natural nutrients to ensure gentleness on sensitive skin. Additionally, the formulations contain colloidal oatmeal (1.0%), a key ingredient known for soothing irritation and maintaining skin moisture.

In May 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Proteologix Inc. for approximately $850 million. This acquisition aims to strengthen Johnson & Johnson's position in treating atopic dermatitis (AD) and asthma by integrating innovative bispecific antibody therapies into its product portfolio. Proteologix Inc. is a US-based biotechnology company specializing in the development of bispecific antibodies for immune-mediated diseases.

Major players in the eczema market are Pfizer Inc., AbbieVie Inc., Bayer AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Amgen, Hoffmann-La Roche AG, Eli Lilly and Co., Siemens Healthineers AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc, Bausch Health Companies Inc., Galderma, Cadila Pharmaceuticals Ltd., LEO Pharma A/S, Almirall, Kyowa Kirin, Alliance Pharma Plc, Encore Dermatology Inc., Arcutis Inc.

North America was the largest region in the eczema market in 2024. The regions covered in eczema report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the eczema market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The eczema market consists of revenues earned by entities by providing services such as diagnosis and consultation services, prescription and medication services, phototherapy services, allergy testing and immunotherapy, and skin barrier repair therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The eczema market also includes sales of antihistamines, topical corticosteroids, calcineurin inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Eczema Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on eczema market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for eczema ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The eczema market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Atopic Dermatitis; Contact Dermatitis; Seborrheic Dermatitis; Other Types
• 2) By Treatment Type: Topical Treatments; Oral Medications; Biologics; Phototherapy
• 3) By Age Group: Children; Adults; Elderly
• 4) By End User: Hospitals Or Clinics; Dermatology Centers; Home Care; Pharmacies
• Subsegments:
• 1) By Atopic Dermatitis: Topical Steroids; Topical Calcineurin Inhibitors; Moisturizers; Biologic Therapies
• 2) By Contact Dermatitis: Topical Steroids; Antihistamines; Topical Immunosuppressants; Wet Compresses
• 3) By Seborrheic Dermatitis: Antifungal Creams or Shampoos; Topical Steroids; Medicated Shampoos; Topical Calcineurin Inhibitors
• 4) By Other Types: Allergic Dermatitis; Nummular Dermatitis; Neurodermatitis; Dyshidrotic Eczema
• Companies Mentioned: Pfizer Inc.; AbbieVie Inc.; Bayer AG; Sanofi S.A; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; GlaxoSmithKline plc; Amgen; Hoffmann-La Roche AG; Eli Lilly and Co.; Siemens Healthineers AG; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Astellas Pharma Inc; Bausch Health Companies Inc.; Galderma; Cadila Pharmaceuticals Ltd.; LEO Pharma A/S; Almirall; Kyowa Kirin; Alliance Pharma Plc; Encore Dermatology Inc.; Arcutis Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.